<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.1.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art510.dtd?><?SourceDTD.Version 5.1.0?><?ConverterInfo.XSLTName elsevier2nlm.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_MOLBIO10357 xml ?><?FILEmain xml ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Biochem Parasitol</journal-id><journal-title>Molecular and Biochemical Parasitology</journal-title><issn pub-type="ppub">0166-6851</issn><issn pub-type="epub">1872-9428</issn><publisher><publisher-name>Elsevier/North-Holland Biomedical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">MOLBIO10357</article-id><article-id pub-id-type="doi">10.1016/j.molbiopara.2009.09.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparative structural, kinetic and inhibitor studies of <italic>Trypanosoma brucei</italic> trypanothione reductase with <italic>T. cruzi</italic><sup><xref ref-type="fn" rid="N0x1da9930N0x2ee6090">&#x02606;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Deuan C.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Ariza</surname><given-names>Antonio</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Chow</surname><given-names>Wing-Huen A.</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Oza</surname><given-names>Sandra L.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Fairlamb</surname><given-names>Alan H.</given-names></name><email>a.h.fairlamb@dundee.ac.uk</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff1"><addr-line><sup>a</sup>College of Life Sciences, The Wellcome Trust Biocentre, University of Dundee, Dundee DD1 5EH, Scotland, UK</addr-line></aff><aff id="aff2"><addr-line><sup>b</sup>Ecole Sup&#x000e9;rieure de Biotechnologie Strasbourg, Parc d&#x02019;Innovation, Boulevard S&#x000e9;bastien Brandt, 67412 Illkirch, France</addr-line></aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. Tel.: +44 1382 38 5155; fax: +44 1382 38 5542. <email>a.h.fairlamb@dundee.ac.uk</email></corresp><fn id="fn1"><label>1</label><p>Current address: York Structural Biology Group, Department of Chemistry, University of York, Heslington, York YO10 5DD, UK.</p></fn></author-notes><pub-date pub-type="ppub"><month>1</month><year>2010</year></pub-date><volume>169</volume><issue>1</issue><fpage>12</fpage><lpage>19</lpage><history><date date-type="received"><day>17</day><month>6</month><year>2009</year></date><date date-type="rev-recd"><day>27</day><month>8</month><year>2009</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2010 Elsevier B.V.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p></license></permissions><abstract><title>Abstract</title><p>As part of a drug discovery programme to discover new treatments for human African trypanosomiasis, recombinant trypanothione reductase from <italic>Trypanosoma brucei</italic> has been expressed, purified and characterized. The crystal structure was solved by molecular replacement to a resolution of 2.3&#x000a0;&#x000c5; and found to be nearly identical to the <italic>T. cruzi</italic> enzyme (root mean square deviation 0.6&#x000a0;&#x000c5; over 482 C&#x003b1; atoms). Kinetically, the <italic>K</italic><sub>m</sub> for trypanothione disulphide for the <italic>T. brucei</italic> enzyme was 4.4-fold lower than for <italic>T. cruzi</italic> measured by either direct (NADPH oxidation) or DTNB-coupled assay. The <italic>K</italic><sub>m</sub> for NADPH for the <italic>T. brucei</italic> enzyme was found to be 0.77&#x000a0;&#x003bc;M using an NADPH-regenerating system coupled to reduction of DTNB. Both enzymes were assayed for inhibition at their respective S&#x000a0;=&#x000a0;<italic>K</italic><sub>m</sub> values for trypanothione disulphide using a range of chemotypes, including CNS-active drugs such as clomipramine, trifluoperazine, thioridazine and citalopram. The relative IC<sub>50</sub> values for the two enzymes were found to vary by no more than 3-fold. Thus trypanothione reductases from these species are highly similar in all aspects, indicating that they may be used interchangeably for structure-based inhibitor design and high-throughput screening.</p></abstract><kwd-group><title>Abbreviations</title><kwd>TryR, trypanothione reductase</kwd><kwd>T(S)<sub>2</sub>, trypanothione disulphide</kwd><kwd>DTNB, 5,5&#x02032;-dithio-bis(2-nitrobenzoic acid)</kwd><kwd>HAT, human African trypanosomiasis</kwd></kwd-group><kwd-group><title>Keywords</title><kwd>Trypanothione metabolism</kwd><kwd>Trypanosome</kwd><kwd>Thiol</kwd><kwd>Enzymology</kwd><kwd>Drug discovery</kwd></kwd-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p><italic>Trypanosoma brucei</italic> is a parasitic protozoan of the family Trypanosomatidae (order Kinetoplastida, suborder Trypanosomatina) responsible for human African trypanosomiasis, also called sleeping sickness. The East and West African forms of the disease are caused by the <italic>T. b. rhodesiense</italic> and <italic>T. b. gambiense</italic> subspecies, respectively <xref rid="bib1" ref-type="bibr">[1]</xref>. The disease is fatal if untreated, and the few available drugs are not ideal due to emerging drug resistance; parenteral administration; toxic side-effects and cost <xref rid="bib2" ref-type="bibr">[2]</xref>. <italic>T. b. brucei</italic>, one of the causative agents of Nagana cattle disease, can serve as a model organism for drug discovery and is non-pathogenic to humans. <italic>T. brucei</italic> subspecies, along with all parasites of the order Kinetoplastida, possesses a novel thiol called trypanothione [<italic>N</italic><sup>1</sup>, <italic>N</italic><sup>8</sup>-bis(glutathionyl)spermidine] <xref rid="bib3" ref-type="bibr">[3]</xref>. One of the major roles of this metabolite is to protect the parasite from oxidative stress by maintaining a reducing environment in the cell. In most other organisms, in particular mammals, it is glutathione that plays this protective role. Protection of the parasite against oxidative stress is achieved through the oxidation of the dithiol form of trypanothione (T(SH)<sub>2</sub>) into the disulphide form (T(S)<sub>2</sub>), followed by regeneration of T(SH)<sub>2</sub> by the NADPH-dependent enzyme trypanothione reductase (TryR) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) <xref rid="bib4" ref-type="bibr">[4]</xref>. A similar mechanism involving glutathione and glutathione reductase is observed in other organisms, including humans. However, the enzymes trypanothione reductase and glutathione reductase are highly specific for their respective disulphide substrates <xref rid="bib5" ref-type="bibr">[5]</xref> such that selective inhibition by small molecules can be readily achieved <xref rid="bib6" ref-type="bibr">[6]</xref>.</p><p>Metabolism of trypanothione and other low molecular weight thiols has been established as an attractive target for drug discovery in several trypanosomatids <xref rid="bib7 bib8 bib9" ref-type="bibr">[7&#x02013;9]</xref> and TryR from <italic>T. b. brucei</italic> has been specifically validated as a drug target, <italic>inter alia</italic>, by conditional knockout experiments <xref rid="bib10" ref-type="bibr">[10]</xref>. However, kinetic and inhibition studies of the <italic>T. b. brucei</italic> enzyme have not been developed. Previously the <italic>T. cruzi</italic> enzyme has been used to guide drug discovery for human African trypanosomiasis (HAT), but absence of a clear correlation between inhibitor potency against <italic>T. cruzi</italic> TryR and cidal activity against bloodstream forms of <italic>T. b. brucei</italic> has raised concerns that the <italic>T. cruzi</italic> enzyme is not a suitable model for the <italic>T. b. brucei</italic> enzyme <xref rid="bib6" ref-type="bibr">[6]</xref>. To address this issue, we report here a comprehensive comparative study of the physicochemical properties, structure, kinetics and inhibitor sensitivities of these enzymes. The information on the enzyme from <italic>T. b. brucei</italic> is also of particular relevance since it is identical at the amino acid level to the putative TryR from <italic>T. b. gambiense</italic>, the causative agent of over 90% of reported HAT cases <xref rid="bib11" ref-type="bibr">[11]</xref>.</p></sec><sec sec-type="materials|methods"><label>2</label><title>Materials and methods</title><sec><label>2.1</label><title>Organisms and reagents</title><p>Routine plasmid manipulations were performed in <italic>Escherichia coli</italic> strain JM109 and over-expression in strain BL21 Star (DE3)pLysS (Invitrogen). All chemicals were of the highest grade available from Sigma, BDH and Molecular Probes. Restriction enzymes and DNA-modifying enzymes were from Promega or Roche.</p></sec><sec><label>2.2</label><title>Cloning and expression TbTryR in <italic>E. coli</italic></title><p>The complete open reading frame of <italic>TbTRYR</italic> was amplified by PCR from genomic DNA from <italic>T. b. brucei</italic> strain S427 (MITat 1.4) using primers based on a putative TryR gene sequence deposited in GeneDB (<bold>Tb10.406.0520</bold>). The primers used for amplification were: 5&#x02032;-<underline>CAT</underline><bold><underline>ATG</underline></bold> TCC AAG GCC TTC GAT TTG G-3&#x02032; and 5&#x02032;-<underline>GGA TCC</underline><bold>TTA</bold> CAG GTT AGA GTC CGG AAG C-3&#x02032;, incorporating the NdeI and BamHI restriction sites (underlined), respectively, with the start and stop codons in bold.</p><p>PCR amplification was done in triplicate. After sequencing, the PCR product of &#x0223c;1.49&#x000a0;kb was then cloned (via a TOPO cloning vector) into the NdeI/BamHI site of pET3a to generate plasmid pET3a-<italic>Tb</italic>TryR. A 4&#x000a0;L culture of BL21 Star (DE3)pLysS/pET3a-<italic>Tb</italic>TryR was grown to test expression and purification. The cells were grown at 37&#x000a0;&#x000b0;C in LB media, containing 50&#x000a0;&#x003bc;g&#x000a0;ml<sup>1</sup> carbenicillin for selection of pET3a and 12.5&#x000a0;&#x003bc;g&#x000a0;ml<sup>1</sup> chloramphenicol for the selection of pLysS, at 37&#x000a0;&#x000b0;C with moderate agitation (200&#x000a0;rpm). A larger scale expression in a 30&#x000a0;L culture was grown in a fermenter (Infors HT) using the same media and antibiotics at 37&#x000a0;&#x000b0;C. When the cultures reached an <italic>A</italic><sub>600</sub> of &#x0223c;0.6, isopropyl-&#x003b2;-<sc>d</sc>-thiogalactopyranoside was added to a final concentration of 0.5&#x000a0;mM. Cultures were grown for an additional 16&#x000a0;h and then harvested by centrifugation at 3480&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> at 4&#x000a0;&#x000b0;C for 30&#x000a0;min and washed in phosphate buffered saline (137&#x000a0;mM NaCl, 2.68&#x000a0;mM KCl, 10.1&#x000a0;mM Na<sub>2</sub>HPO<sub>4</sub>, 1.76&#x000a0;mM KH<sub>2</sub>PO<sub>4</sub>).</p></sec><sec><label>2.3</label><title>Purification of TbTryR</title><p><italic>E. coli</italic> cells were lysed using a one-shot cell disruptor (Constant Systems Ltd.). Purification of recombinant <italic>Tb</italic>TryR was achieved by a combination of ammonium sulphate purification, affinity chromatography on 2&#x02032;5&#x02032;-ADP Sepharose, and anion exchange chromatography essentially as described previously <xref rid="bib12" ref-type="bibr">[12]</xref>. Purity was assessed by SDS-PAGE.</p><p><italic>Tb</italic>TryR was used directly from this procedure for crystallography, analysis of flavin content and measurement of extinction coefficient. The remainder of the TryR was precipitated with 70% saturating ammonium sulphate and aliquotted for storage at 4&#x000a0;&#x000b0;C for subsequent use in kinetic experiments. Protein concentration was measured using the method of Bradford with bovine serum albumin as a standard <xref rid="bib13" ref-type="bibr">[13]</xref>.</p></sec><sec><label>2.4</label><title>Assessment of oligomeric state</title><p><italic>Tb</italic>TryR (600&#x000a0;&#x003bc;g) was applied to a gel filtration column (Superdex 200 10/300 GE Healthcare) previously equilibrated with 25&#x000a0;mM HEPES pH 7.5 containing 100&#x000a0;mM NaCl. Elution of the column was monitored at 280&#x000a0;nm using an Akta purifier. Molecular weight was inferred from comparison with standards (BioRad gel filtration standard) on a plot of elution volume versus Log molecular weight. Samples of the recombinant enzyme were also analysed by analytical ultracentrifugation (Analytical ultracentrifugation service, College of Life Sciences, University of Dundee).</p></sec><sec><label>2.5</label><title>Absorbance spectra and determination of absorption coefficient</title><p>All spectra were carried out in a UV-1601pc temperature-regulated spectrophotometer (Shimadzu) using 1-cm path-length quartz cuvettes (200&#x000a0;&#x003bc;l sample volume). Enzymes were extensively dialysed against 40&#x000a0;mM HEPES pH 7.4, 1&#x000a0;mM EDTA. Absorbance spectra were acquired over a range of 200&#x02013;800&#x000a0;nm. The enzyme-associated flavin was liberated by thermal denaturation at 100&#x000a0;&#x000b0;C for 20&#x000a0;min in the presence of 10&#x000a0;mM MgCl<sub>2</sub>. Denatured protein was removed by microcentrifugation and the concentration of free flavin determined from its absorption coefficient at 450&#x000a0;nm (11.3&#x000a0;mM<sup>&#x02212;1</sup>&#x000a0;cm<sup>&#x02212;1</sup>). The absorption coefficient of oxidised <italic>Tb</italic>TryR was calculated from the absorbance at 463&#x000a0;nm/[FAD] in triplicate samples. The absorption coefficient of NADPH-reduced <italic>Tb</italic>TryR at 530&#x000a0;nM was calculated from the absorbance at 530&#x000a0;nm/[FAD].</p></sec><sec><label>2.6</label><title>Enzyme assays</title><p>TryR was assayed spectrophotometrically either by monitoring the trypanothione-dependent oxidation of NADPH at 340&#x000a0;nm <xref rid="bib14" ref-type="bibr">[14]</xref>, or by the reduction of 5,5&#x02032;-dithio-bis(2-nitrobenzoic acid) (DTNB) at 412&#x000a0;nm (see <xref rid="fig1" ref-type="fig">Fig. 1</xref>B) <xref rid="bib15" ref-type="bibr">[15]</xref>. Assays at 340&#x000a0;nm were carried out at 25&#x000a0;&#x000b0;C in 500&#x000a0;&#x003bc;l volume acrylic cuvettes and changes in absorbance monitored with a UV-1601 PC spectrophotometer (Shimadzu). The standard assay mixture contained 40&#x000a0;mM HEPES pH 7.4, 1&#x000a0;mM EDTA, &#x0223c;10&#x000a0;mU&#x000a0;ml<sup>&#x02212;1</sup> TryR, 150&#x000a0;&#x003bc;M NADPH and 100&#x000a0;&#x003bc;M T(S)<sub>2</sub>. Assays at 412&#x000a0;nm were carried out in 96-well plates (Polysorp, Nunc) at room temperature in a volume of 200&#x000a0;&#x003bc;l. Changes in absorbance were monitored in a SpectraMax 340pc plate reader (Molecular Devices). The standard assay mixture contained 40&#x000a0;mM HEPES pH 7.4, 1&#x000a0;mM EDTA, &#x0223c;10&#x000a0;mU&#x000a0;ml<sup>&#x02212;1</sup> TryR, 150&#x000a0;&#x003bc;M NADPH, 6&#x000a0;&#x003bc;M T(S)<sub>2</sub> and 50&#x000a0;&#x003bc;M DTNB. All assays were initiated by addition of the T(S)<sub>2</sub>. Data was collected using SoftMax Pro (molecular devices) and UVProbe 2 (Shimadzu) software, processed and analysed using Excel 2002 (Microsoft) and GraFit 5 (Erithacus Software). NADPH stock solutions were measured spectrophotometrically at 340&#x000a0;nm using an absorption coefficient of 6.22&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup>&#x000a0;M<sup>&#x02212;1</sup>&#x000a0;cm<sup>&#x02212;1</sup><xref rid="bib16" ref-type="bibr">[16]</xref>. The concentration of T(S)<sub>2</sub> stock solutions were determined by measuring the oxidation of NADPH in the presence of excess TryR.</p></sec><sec><label>2.7</label><title><italic>K</italic><sub>m</sub> analyses</title><p><italic>K</italic><sub>m</sub> values with respect to T(S)<sub>2</sub> were determined for <italic>Tb</italic>TryR in both assays using purified recombinant <italic>T. cruzi</italic> TryR for comparison <xref rid="bib12" ref-type="bibr">[12]</xref>. Determinations for each enzyme were carried out in three independent experiments and a weighted mean calculated. T(S)<sub>2</sub> concentration was varied from 5&#x000a0;&#x000d7;&#x000a0;<italic>K</italic><sub>m</sub> to 0.5&#x000a0;&#x000d7;&#x000a0;<italic>K</italic><sub>m</sub>.</p><p>Substrate specificity in the 412&#x000a0;nm DTNB-coupled assay was investigated by comparing the reaction velocity in the standard assay mixture with reactions where 150&#x000a0;&#x003bc;M NADH was substituted for the NADPH and by comparing velocities of reactions containing 50&#x000a0;&#x003bc;M glutathione disulphide or 50&#x000a0;&#x003bc;M T(S)<sub>2</sub>. Values are presented as the mean and standard deviation of four replicates.</p><p>In order to determine <italic>K</italic><sub>m</sub> with respect to NADPH using the 412&#x000a0;nm DTNB assay, NADPH levels were maintained constant using glucose-6-phosphate and glucose-6-phosphate dehydrogenase from <italic>Saccharomyces cerevisiae</italic><xref rid="bib17" ref-type="bibr">[17]</xref>. Preliminary experiments over a range of NADPH concentrations (0.5&#x02013;150&#x000a0;&#x003bc;M) established that 200&#x000a0;mU&#x000a0;ml<sup>&#x02212;1</sup> of glucose-6-phosphate dehydrogenase was non-limiting (plateaux region of reaction velocity versus mU&#x000a0;ml<sup>&#x02212;1</sup>) and therefore chosen for determination of <italic>K</italic><sub>m</sub> with respect to NADPH. The final assay mixture contained 40&#x000a0;mM HEPES pH 7.4, 1&#x000a0;mM EDTA, &#x0223c;10&#x000a0;mU&#x000a0;ml<sup>&#x02212;1</sup> TryR, 6&#x000a0;&#x003bc;M T(S)<sub>2</sub>, 50&#x000a0;&#x003bc;M DTNB and 0.2&#x02013;200&#x000a0;&#x003bc;M NADPH (7-point 3-fold serial dilution). Assays were initiated by addition of the NADPH. <italic>K</italic><sub>m</sub> values with respect to NADPH were determined for <italic>Tb</italic>TryR in three independent experiments and a weighted mean calculated.</p></sec><sec><label>2.8</label><title>Enzyme inhibition studies</title><p>Inhibitor concentrations giving 50% inhibition (IC<sub>50</sub>) were determined using the 412&#x000a0;nm assay with the standard assay mixture modified to contain T(S)<sub>2</sub> at [S]&#x000a0;=&#x000a0;<italic>K</italic><sub>m</sub>. Assay plates were prepared using a Precision2000 liquid handler (Bio-Tek) with a final DMSO concentration of 1% in all wells. Plates contained a 10-point serial dilution (2-fold or 3-fold dilutions) across columns 2&#x02013;11 with a top concentration of 100&#x000a0;&#x003bc;M or 200&#x000a0;&#x003bc;M. Seven compounds were tested per plate in rows A&#x02013;G, row H was used for a clomipramine control on each plate. Column 1 contained full signal controls (no inhibitor) and column 12 contained background controls (no enzyme). All compounds were tested on three separate occasions and the results reported as weighted means. <italic>Z</italic>&#x02032; figures were calculated from the full signal and background controls <xref rid="bib18" ref-type="bibr">[18]</xref>.</p></sec><sec><label>2.9</label><title>Assessment of mode of inhibition</title><p>Clomipramine was tested for mode of inhibition with respect to T(S)<sub>2</sub>. The standard 412&#x000a0;nm DTNB-coupled assay was used with the following modifications. Aliquots of the assay mixture (180&#x000a0;&#x003bc;l) containing 0&#x000a0;&#x003bc;M, 1&#x000a0;&#x003bc;M, 2&#x000a0;&#x003bc;M and 4&#x000a0;&#x003bc;M clomipramine were added to four rows of a microtitre plate, respectively. T(S)<sub>2</sub> was serially diluted across a fifth row of the plate to produce a 12-point range from 500&#x000a0;&#x003bc;M to 5.8&#x000a0;&#x003bc;M. The assay was initiated by transferring 20&#x000a0;&#x003bc;l of the T(S)<sub>2</sub> row to each of the assay rows. The final 200&#x000a0;&#x003bc;l assay contained 150&#x000a0;&#x003bc;M NADPH, 50&#x000a0;&#x003bc;M DTNB, 10&#x000a0;mU&#x000a0;ml<sup>&#x02212;1</sup> TryR and 50&#x02013;0.58&#x000a0;&#x003bc;M T(S)<sub>2</sub>. The rate of reaction was measured as before. Each data set was fitted by non-linear regression to the Michaelis&#x02013;Menten equation using GraFit 5.0 (Erithacus software). The resulting individual fits were examined as Lineweaver&#x02013;Burke transformations and the graphs inspected to confirm competitive inhibition mode (intersection on <italic>y</italic>-axis). The entire data set was then globally fitted to the competitive-mode equation.</p></sec><sec><label>2.10</label><title>Growth inhibition studies</title><p>The effective concentration of compounds inhibiting cell growth by 50% (EC<sub>50</sub>) was determined as previously described <xref rid="bib19 bib20" ref-type="bibr">[19,20]</xref>. Bloodstream form <italic>T. b. brucei</italic> cells (strain 427, &#x02018;single marker&#x02019;) were grown at 37&#x000a0;&#x000b0;C and 5% CO<sub>2</sub> in a modified HMI9 <xref rid="bib21" ref-type="bibr">[21]</xref> (HMI9-T where 0.2&#x000a0;mM 2-mercaptoethanol was replaced with 0.056&#x000a0;mM thioglycerol). Stock cultures were maintained in T75 vented cap culture flasks (Greiner, Kremsmuenster, Austria) and sub-cultured every 48&#x02013;72&#x000a0;h by dilution into fresh medium. For microtitre plate assays, cells were counted using a Casy cell counter TT (Sch&#x000e4;rfe systems) and diluted appropriately. Compounds were tested in 96-well test plates (Greiner). The final conditions were 50&#x02013;0.07&#x000a0;&#x003bc;M test compound (9-point 3-fold serial dilutions), 0.5% DMSO, 10<sup>3</sup>&#x000a0;ml<sup>&#x02212;1</sup> cells in a total volume of 0.2&#x000a0;ml. Plates were incubated for 3 days, resazurin was added to a final concentration of 45&#x000a0;&#x003bc;M and plates incubated for a further 4&#x000a0;h. Fluorescence was measured at 528&#x000a0;nm excitation and 590&#x000a0;nm emission. EC<sub>50</sub> values were determined in three separate experiments and the data reported as weighted means.</p></sec><sec><label>2.11</label><title>Crystallography</title><p><italic>Tb</italic>TryR was concentrated to 12.4&#x000a0;mg<sup>&#x02212;1</sup>&#x000a0;ml in 20&#x000a0;mM bis-Tris buffer pH 7.0 containing 95&#x000a0;mM KCl, 1&#x000a0;mM EDTA and 1&#x000a0;mM DTT. The protein was crystallised by the hanging drop vapour-diffusion method at 20&#x000a0;&#x000b0;C using 24-well VDX plates with 500&#x000a0;&#x003bc;l of reservoir solution. Crystals were cryoprotected by sequential immersion for 5&#x000a0;s into a 3-&#x003bc;l drop containing 0.1&#x000a0;M bis-Tris propane pH 8.0, 5% PEG 400, 1&#x000a0;M ammonium sulphate plus 10% glycerol, then the same solution plus 20% glycerol and finally into another drop with 30% glycerol before flash-freezing them in liquid nitrogen. High resolution X-ray data to 2.3&#x000a0;&#x000c5; was collected at with a MicroMax-007HF X-ray generator (Rigaku) and an R-axis IV detector (Rigaku) at a wavelength of 1.5428&#x000a0;&#x000c5;. The X-ray data was integrated using MOSFLM <xref rid="bib22" ref-type="bibr">[22]</xref>, scaled with SCALA <xref rid="bib23" ref-type="bibr">[23]</xref>, and the structure solved using the <italic>Tc</italic>TryR structure <xref rid="bib18 bib24" ref-type="bibr">[18,24]</xref>, which shares 84% sequence similarity with <italic>Tb</italic>TryR, as the input model for molecular replacement with MOLREP <xref rid="bib25" ref-type="bibr">[25]</xref>. Model building was carried out with COOT <xref rid="bib26" ref-type="bibr">[26]</xref> and structure refinement with REFMAC5 <xref rid="bib27 bib28" ref-type="bibr">[27,28]</xref>.</p></sec></sec><sec><label>3</label><title>Results and discussion</title><sec><label>3.1</label><title>Cloning and expression</title><p>The gene encoding TryR was cloned from <italic>T. b. brucei</italic> strain 427 and found to be identical with that from the genome sequencing strain 927, apart from nucleotide substitutions of C for T at position 105 and A for G at position 906. Nevertheless, the two sequences are identical at the amino acid level. As noted above, TryR from <italic>T. b. gambiense</italic> is also identical at the amino acid level.</p><p><italic>Tb</italic>TryR was expressed in a 4&#x000a0;L culture of <italic>E. coli</italic> strain BL21 Star(DE3)pLysS competent cells and purified to apparent homogeneity (<xref rid="fig2" ref-type="fig">Fig. 2</xref> and <xref rid="tbl1" ref-type="table">Table 1</xref>). The specific activity of the purified enzyme (91&#x000a0;U&#x000a0;mg<sup>&#x02212;1</sup>) is similar that of the <italic>T. cruzi</italic> (143&#x000a0;U&#x000a0;mg<sup>&#x02212;1</sup>) <xref rid="bib12" ref-type="bibr">[12]</xref> and <italic>L. donovani</italic> (113&#x000a0;U&#x000a0;mg<sup>&#x02212;1</sup>) <xref rid="bib29" ref-type="bibr">[29]</xref>. The overall yield of 7.6&#x000a0;mg&#x000a0;l<sup>&#x02212;1</sup> is similar to the <italic>T. cruzi</italic> enzyme (19.0&#x000a0;mg&#x000a0;l<sup>&#x02212;1</sup>) <xref rid="bib12" ref-type="bibr">[12]</xref> and <italic>T. congolense</italic> (3.2&#x000a0;mg&#x000a0;l<sup>&#x02212;1</sup>) <xref rid="bib30" ref-type="bibr">[30]</xref>. Scaling up expression in a 30&#x000a0;L fermenter culture yielded 8.8&#x000a0;mg&#x000a0;l<sup>&#x02212;1</sup> TbTryR.</p></sec><sec><label>3.2</label><title>Analysis of oligomeric state</title><p>The subunit mass of <italic>Tb</italic>TryR was calculated as 53,156&#x000a0;Da. Gel filtration revealed 86% of the sample eluting at a volume corresponding to 96&#x000a0;kDa (data not shown). Analytical ultracentrifugation indicated 90% of the sample was present at a molecular weight of approximately 93&#x000a0;kDa (data not shown). Both techniques therefore indicated the protein was almost entirely present as a dimer in solution.</p></sec><sec><label>3.3</label><title>Spectroscopic analysis</title><p>Recombinant <italic>Tb</italic>TryR possesses spectral properties closely resembling those of other trypanothione reductases (<xref rid="tbl2" ref-type="table">Table 2</xref> and <xref rid="fig3" ref-type="fig">Fig. 3</xref>) <xref rid="bib31 bib32" ref-type="bibr">[31,32]</xref>. The oxidised enzyme (<xref rid="fig3" ref-type="fig">Fig. 3</xref> solid line), where the redox-active cysteine residues, Cys52 and Cys57, within the disulphide binding site are covalently linked in a disulphide bridge, exhibits maxima at 273, 378 and 463&#x000a0;nm and a shoulder at 486&#x000a0;nm indicative of a flavoprotein <xref rid="bib32" ref-type="bibr">[32]</xref>. Thermal liberation of the flavin prosthetic group yielded a mean absorption coefficient for the oxidised enzyme of 11.4&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;mM<sup>&#x02212;1</sup>&#x000a0;cm<sup>&#x02212;1</sup> at 463&#x000a0;nm (<italic>n</italic>&#x000a0;=&#x000a0;4). Addition of excess NADPH (2&#x000a0;mM, <xref rid="fig3" ref-type="fig">Fig. 3</xref> dotted line), leads to a decrease in the absorbance at 463&#x000a0;nm with concomitant acquisition of a broad long-wavelength absorption band at 530&#x000a0;nm due to reduction of the cysteine disulphide bridge and accompanying formation of a characteristic charge transfer complex between the FAD and the proximal sulphydryl group of Cys57 <xref rid="bib29" ref-type="bibr">[29]</xref>. This spectrum is stable indefinitely in the presence of excess NADPH.</p></sec><sec><label>3.4</label><title>Substrate analysis</title><p>The <italic>K</italic><sub>m</sub> values for T(S)<sub>2</sub> with saturating NADPH in both the 340 and 412&#x000a0;nm assays were compared with <italic>T. cruzi</italic> TryR (<xref rid="tbl2" ref-type="table">Table 2</xref>). The <italic>K</italic><sub>m</sub> values for the <italic>T. cruzi</italic> enzyme were 4.3- and 4.4-fold greater in each assay, respectively.</p><p><italic>Tb</italic>TryR was highly specific for the electron donor (NADPH) and electron acceptor (T(S)<sub>2</sub>) in the 412&#x000a0;nm assay. Activity with 150&#x000a0;&#x003bc;M NADH was only 5.7% of that obtained with 150&#x000a0;&#x003bc;M NADPH and the rate of reduction of 50&#x000a0;&#x003bc;M glutathione disulphide was 0.03% of that obtained with 50&#x000a0;&#x003bc;M T(S)<sub>2</sub>.</p><p>We were unable to reliably determine a <italic>K</italic><sub>m</sub> with respect to NADPH in either the 340&#x000a0;nm direct assay or the 412&#x000a0;nm DTNB-coupled assay due to the short periods of linearity at low NADPH concentrations. Hence we developed a modified 412&#x000a0;nm DTNB-coupled assay wherein the NADPH level was maintained constant by inclusion of glucose-6-phosphate and glucose-6-phosphate dehydrogenase (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C). The apparent <italic>K</italic><sub>m</sub> for NADPH determined in this modified assay was 0.77&#x000a0;&#x003bc;M.</p><p>The specificity constant (<italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub>) for the <italic>T. b. brucei</italic> enzyme (8.7&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;M<sup>&#x02212;1</sup>&#x000a0;s<sup>&#x02212;1</sup>) compares favourably with the previously reported values for <italic>T. cruzi</italic> (5.2&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;M<sup>&#x02212;1</sup>&#x000a0;<sup>&#x02212;1</sup>) <xref rid="bib12 bib31" ref-type="bibr">[12,31]</xref> and <italic>L. donovani</italic> (5.0&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;M<sup>&#x02212;1</sup>&#x000a0;s<sup>&#x02212;1</sup>) <xref rid="bib29" ref-type="bibr">[29]</xref>. (Note that the lower value determined here for <italic>T. cruzi</italic> (2.6&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;M<sup>&#x02212;1</sup>&#x000a0;s<sup>&#x02212;1</sup>; <xref rid="tbl2" ref-type="table">Table 2</xref>) is due to loss of &#x0223c;50% activity on prolonged storage at 4&#x000a0;&#x000b0;C as an ammonium sulphate suspension.)</p></sec><sec><label>3.5</label><title>Inhibitor testing</title><p>In order to identify potential differences in the sensitivity of trypanothione reductases from <italic>T. b. brucei</italic> and <italic>T. cruzi</italic> to small-molecule inhibitors, ten compounds spanning a range of inhibitor chemotypes, were tested for potency (IC<sub>50</sub> values) against the two enzymes at T(S)<sub>2</sub> concentrations equivalent to their respective <italic>K</italic><sub>m</sub> values. With these ten inhibitors the maximum difference between sensitivity of the two enzymes was 3.3-fold (<xref rid="tbl3" ref-type="table">Table 3</xref> and <xref rid="fig4" ref-type="fig">Fig. 4</xref>). The mode of inhibition by clomipramine was confirmed as competitive for T(S)<sub>2</sub> by measuring reaction velocity while varying T(S)<sub>2</sub> at a range of clomipramine concentrations (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). The <italic>K</italic><sub>i</sub> value from three independent experiments yielded a mean weighted to standard error of 3.03&#x000a0;&#x000b1;&#x000a0;0.28&#x000a0;&#x003bc;M. This is similar to the calculated <italic>K</italic><sub>i</sub> value of 5.5&#x000a0;&#x003bc;M from our IC<sub>50</sub> determination (for a competitive inhibitor at [S]&#x000a0;=&#x000a0;<italic>K</italic><sub>m</sub>, IC<sub>50</sub>&#x000a0;=&#x000a0;2&#x000a0;&#x000d7;&#x000a0;<italic>K</italic><sub>m</sub>).</p><p>Ebselen, clomipramine and the four compounds DM5a; DM6a; DM7a and DM8a were known to be active against an <italic>in vitro</italic> assay of <italic>T. b. brucei</italic> proliferation <xref rid="bib19 bib33" ref-type="bibr">[19,33]</xref>. Under identical conditions, the concentration inhibiting 50% growth (EC<sub>50</sub>) was determined here for three of the remaining TryR inhibitors, all of which were active in the single-figure micromolar range (<xref rid="tbl3" ref-type="table">Table 3</xref>). Despite the use of <italic>Tb</italic>TryR in place of <italic>Tc</italic>TryR used in previous studies <xref rid="bib6" ref-type="bibr">[6]</xref>, correlation between TryR inhibition and trypanocidal activity remains modest at best (<italic>r</italic><sup>2</sup>&#x000a0;=&#x000a0;0.49). This indicates either significant differences in the uptake of these compounds or, more likely, that some of these compounds inhibit other targets within the cell.</p><p>Several of the compounds used in our study are currently in clinical use or have undergone human clinical trials; for example ebselen is being evaluated for the treatment of acute ischemic stroke <xref rid="bib34" ref-type="bibr">[34]</xref>. Thioridazine, trifluoperazine and clomipramine have been previously identified as inhibitors of <italic>Tc</italic>TryR <xref rid="bib35 bib36" ref-type="bibr">[35,36]</xref>. Although these CNS-active drugs show potent trypanocidal activity <italic>in vitro</italic>, thioridazine (50&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup>, i.p.) and trifluoperazine (50&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup>, i.p.) are inactive in the chronic mouse model of African trypanosomiasis <xref rid="bib37" ref-type="bibr">[37]</xref> and clomipramine (50&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup>, i.p.) failed to extend survival time by even one day in the acute mouse model (Halliburton and Fairlamb, unpublished). To our knowledge the structurally distinct antidepressant citalopram has not been tested <italic>in vivo</italic>. Despite the lack of <italic>in vivo</italic> activity, these molecules represent useful potential starting points for drug development for HAT, particularly as they are likely to cross the blood&#x02013;brain barrier and therefore could be active against the late stage of the disease.</p></sec><sec><label>3.6</label><title>Crystallography</title><p>Large crystals (approximately 0.8&#x000a0;mm&#x000a0;&#x000d7;&#x000a0;0.3&#x000a0;mm&#x000a0;&#x000d7;&#x000a0;0.05&#x000a0;mm) diffracting to 2.3&#x000a0;&#x000c5; were obtained in drops containing 2.0&#x000a0;&#x003bc;l of protein solution plus 1.0&#x000a0;&#x003bc;l reservoir solution, where the reservoir consisted of 0.1&#x000a0;M bis-Tris propane pH 8.0, 5% PEG 400, 2&#x000a0;M ammonium sulphate. Diffraction data was solved by molecular replacement using the <italic>Tc</italic>TryR structure; the overall statistics of the final <italic>Tb</italic>TryR model are given in <xref rid="tbl4" ref-type="table">Table 4</xref>. <italic>Tb</italic>TryR is a homodimer and each subunit of the final model comprises 489 amino acid residues, 1 FAD, 1 NADPH, 4 glycerol and 1 sulphate molecules. Also present are 786 solvent positions that were modelled as oxygen atoms and 1 PEG400 molecule (associated with subunit A). The first residue and the last 2 residues in both subunits were excluded from the structure as there was no convincing electron density to model. The same applies to the nicotinamide moieties of the two NADPH molecules, which were not included in the final model. The overall structure of <italic>Tb</italic>TryR (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A) is nearly identical to that of <italic>Tc</italic>TryR (rmsd&#x000a0;=&#x000a0;0.6&#x000a0;&#x000c5; over 482 C&#x003b1; atoms). All the catalytically important residues (Cys52, Cys57 and His461) and residues interacting with T(S)<sub>2,</sub> including those involved in binding the spermidine moiety (Leu17, Glu18, Trp21, Met 113, Ser109, Tyr110) <xref rid="bib24" ref-type="bibr">[24]</xref> are conserved between both structures (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B).</p></sec></sec><sec><label>4</label><title>Conclusion</title><p>In conclusion, the kinetic and physical properties of <italic>Tb</italic>TryR are consistent with trypanothione reductases from other trypanosomatids such as <italic>T. cruzi</italic> and <italic>L. donovani</italic>, especially the striking preference for T(S)<sub>2</sub> over glutathione disulphide. We have observed no significant differences between the <italic>Tb</italic>TryR and <italic>Tc</italic>TryR in terms of <italic>K</italic><sub>m</sub>, sensitivity to inhibitors or in crystal structure. Thus, either enzyme may be used as an effective surrogate for the other in high-throughput screening <xref rid="bib6 bib19 bib33 bib38" ref-type="bibr">[6,19,33,38]</xref> and structure-based inhibitor design as part of a drug discovery campaign against human African trypanosomiasis or Chagas&#x02019; disease. One of Lipinski's &#x0201c;Rule of 5&#x0201d; <xref rid="bib39" ref-type="bibr">[39]</xref> states that, for an orally bioavailable drug, the molecular mass should ideally be under 500&#x000a0;Da. Thus, one major challenge with druggability of this target is the large size of the active site, which must accommodate the substrates, T(S)<sub>2</sub> (721&#x000a0;Da) or glutathionylspermidine disulphide (867 Da). In addition, a second challenge is the potential for displacement of reversible inhibitors from TryR by accumulation of T(S)<sub>2</sub> as a consequence of further cellular metabolism of T[SH]<sub>2</sub>. Although we have now identified competitive inhibitors with <italic>K</italic><sub>i</sub> values &#x0223c;250&#x000a0;nM <xref rid="bib33 bib40" ref-type="bibr">[33,40]</xref>, theoretical calculations based on T[SH]<sub>2</sub> concentrations in the cell suggest that <italic>K</italic><sub>i</sub> values &#x0223c;1&#x02013;10&#x000a0;nM are required to sustain &#x0003e;90% inhibition in the face of accumulating T[S]<sub>2</sub>. Alternatively, irreversible active site directed inhibitors are required. Either strategy would be greatly enhanced with knowledge of the binding mode of inhibitors in the active site pocket of the enzyme. Details will be reported in subsequent publications.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to acknowledge Dr Ahilan Saravanamuthu for preliminary studies and Dr Tim Vickers for helpful discussions.</p><p>This work was supported by the Wellcome Trust (WT079838 and WT083481) and the Drugs for Neglected Diseases initiative.</p></ack><fn-group><fn id="N0x1da9930N0x2ee6090"><label>&#x02606;</label><p><italic>Note:</italic> Crystallographic data have been deposited on PDB with the accession code 2wba.</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><label>[1]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>K.D.</given-names></name><name><surname>Brun</surname><given-names>R.</given-names></name><name><surname>Croft</surname><given-names>S.L.</given-names></name></person-group><article-title>Kinetoplastids: related protozoan pathogens, different diseases</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><fpage>1301</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">18382742</pub-id></citation></ref><ref id="bib2"><label>[2]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Renslo</surname><given-names>A.R.</given-names></name><name><surname>McKerrow</surname><given-names>J.H.</given-names></name></person-group><article-title>Drug discovery and development for neglected parasitic diseases</article-title><source>Nat Chem Biol</source><year>2006</year><volume>2</volume><fpage>701</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">17108988</pub-id></citation></ref><ref id="bib3"><label>[3]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fairlamb</surname><given-names>A.H.</given-names></name><name><surname>Blackburn</surname><given-names>P.</given-names></name><name><surname>Ulrich</surname><given-names>P.</given-names></name></person-group><article-title>Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids</article-title><source>Science</source><year>1985</year><volume>227</volume><fpage>1485</fpage><lpage>1487</lpage><pub-id pub-id-type="pmid">3883489</pub-id></citation></ref><ref id="bib4"><label>[4]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fairlamb</surname><given-names>A.H.</given-names></name><name><surname>Cerami</surname><given-names>A.</given-names></name></person-group><article-title>Metabolism and functions of trypanothione in the Kinetoplastida</article-title><source>Annu Rev Microbiol</source><year>1992</year><volume>46</volume><fpage>695</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">1444271</pub-id></citation></ref><ref id="bib5"><label>[5]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>G.B.</given-names></name><name><surname>Fairlamb</surname><given-names>A.H.</given-names></name><name><surname>Ulrich</surname><given-names>P.</given-names></name></person-group><article-title>Substrate specificity of the flavoprotein trypanothione disulfide reductase from Crithidia fasciculata</article-title><source>Biochemistry</source><year>1987</year><volume>26</volume><fpage>3023</fpage><lpage>3027</lpage><pub-id pub-id-type="pmid">3607007</pub-id></citation></ref><ref id="bib6"><label>[6]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>G.A.</given-names></name><name><surname>Baell</surname><given-names>J.B.</given-names></name><name><surname>Fairlamb</surname><given-names>A.H.</given-names></name></person-group><article-title>Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening</article-title><source>Bioorg Med Chem Lett</source><year>2007</year><volume>17</volume><fpage>1422</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">17194585</pub-id></citation></ref><ref id="bib7"><label>[7]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Silva</surname><given-names>C.</given-names></name><name><surname>Daunes</surname><given-names>S.</given-names></name></person-group><article-title>The therapeutic potential of inhibitors of the trypanothione cycle</article-title><source>Expert Opin Investig Drugs</source><year>2002</year><volume>11</volume><fpage>217</fpage><lpage>231</lpage></citation></ref><ref id="bib8"><label>[8]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Augustyns</surname><given-names>K.</given-names></name><name><surname>Amssoms</surname><given-names>K.</given-names></name><name><surname>Yamani</surname><given-names>A.</given-names></name></person-group><article-title>Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents</article-title><source>Curr Pharm Des</source><year>2001</year><volume>7</volume><fpage>1117</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">11472257</pub-id></citation></ref><ref id="bib9"><label>[9]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steenkamp</surname><given-names>D.J.</given-names></name><name><surname>Weldrick</surname><given-names>D.P.</given-names></name><name><surname>Pletschke</surname><given-names>B.</given-names></name></person-group><article-title>Thiol metabolism of the trypanosomatids as potential drug targets</article-title><source>S Afr J Sci</source><year>1998</year><volume>94</volume><fpage>281</fpage><lpage>283</lpage></citation></ref><ref id="bib10"><label>[10]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krieger</surname><given-names>S.</given-names></name><name><surname>Schwarz</surname><given-names>W.</given-names></name><name><surname>Ariyanayagam</surname><given-names>M.R.</given-names></name></person-group><article-title>Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress</article-title><source>Mol Microbiol</source><year>2000</year><volume>35</volume><fpage>542</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">10672177</pub-id></citation></ref><ref id="bib11"><label>[11]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simarro</surname><given-names>P.P.</given-names></name><name><surname>Jannin</surname><given-names>J.</given-names></name><name><surname>Cattand</surname><given-names>P.</given-names></name></person-group><article-title>Eliminating human African trypanosomiasis: where do we stand and what comes next?</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>174</fpage><lpage>180</lpage></citation></ref><ref id="bib12"><label>[12]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>A.</given-names></name><name><surname>Cunningham</surname><given-names>M.L.</given-names></name><name><surname>Tovar</surname><given-names>J.</given-names></name></person-group><article-title>Site-directed mutagenesis of the redox-active cysteines of Trypanosoma cruzi trypanothione reductase</article-title><source>Eur J Biochem</source><year>1995</year><volume>228</volume><fpage>745</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">7737173</pub-id></citation></ref><ref id="bib13"><label>[13]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradford</surname><given-names>M.M.</given-names></name></person-group><article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein&#x02013;dye binding</article-title><source>Anal Biochem</source><year>1976</year><volume>72</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">942051</pub-id></citation></ref><ref id="bib14"><label>[14]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jockers-Scherubl</surname><given-names>M.C.</given-names></name><name><surname>Schirmer</surname><given-names>R.H.</given-names></name><name><surname>Krauth-Siegel</surname><given-names>R.L.</given-names></name></person-group><article-title>Trypanothione reductase from Trypanosoma cruzi: catalytic properties of the enzyme and inhibition studies with trypanocidal compounds</article-title><source>Eur J Biochem</source><year>1989</year><volume>180</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">2647489</pub-id></citation></ref><ref id="bib15"><label>[15]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>C.J.</given-names></name><name><surname>Saravanamuthu</surname><given-names>A.</given-names></name><name><surname>Eggleston</surname><given-names>I.M.</given-names></name></person-group><article-title>Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase</article-title><source>Biochem J</source><year>2003</year><volume>369</volume><fpage>529</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">12416994</pub-id></citation></ref><ref id="bib16"><label>[16]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moroff</surname><given-names>G.</given-names></name><name><surname>Ochs</surname><given-names>R.S.</given-names></name><name><surname>Brandt</surname><given-names>K.G.</given-names></name></person-group><article-title>Yeast glutathione reductase. Steady-state kinetic studies of its transhydrogenase activity</article-title><source>Arch Biochem Biophys</source><year>1976</year><volume>173</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">4035</pub-id></citation></ref><ref id="bib17"><label>[17]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghigo</surname><given-names>D.</given-names></name><name><surname>Riganti</surname><given-names>C.</given-names></name><name><surname>Gazzano</surname><given-names>E.</given-names></name></person-group><article-title>Cycling of NADPH by glucose 6-phosphate dehydrogenase optimizes the spectrophotometric assay of nitric oxide synthase activity in cell lysates</article-title><source>Nitric Oxide</source><year>2006</year><volume>15</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">16483808</pub-id></citation></ref><ref id="bib18"><label>[18]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.H.</given-names></name><name><surname>Chung</surname><given-names>T.D.Y.</given-names></name><name><surname>Oldenburg</surname><given-names>K.R.</given-names></name></person-group><article-title>A simple statistical parameter for use in evaluation and validation of high throughput screening assays</article-title><source>J Biomol Screen</source><year>1999</year><volume>4</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">10838414</pub-id></citation></ref><ref id="bib19"><label>[19]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martyn</surname><given-names>D.C.</given-names></name><name><surname>Jones</surname><given-names>D.C.</given-names></name><name><surname>Fairlamb</surname><given-names>A.H.</given-names></name></person-group><article-title>High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity</article-title><source>Bioorg Med Chem Lett</source><year>2007</year><volume>17</volume><fpage>1280</fpage><lpage>1283</lpage><pub-id pub-id-type="pmid">17197182</pub-id></citation></ref><ref id="bib20"><label>[20]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raz</surname><given-names>B.</given-names></name><name><surname>Iten</surname><given-names>M.</given-names></name><name><surname>Grether-Buhler</surname><given-names>Y.</given-names></name></person-group><article-title>The Alamar Blue&#x000ae; assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro</article-title><source>Acta Trop</source><year>1997</year><volume>68</volume><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">9386789</pub-id></citation></ref><ref id="bib21"><label>[21]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirumi</surname><given-names>H.</given-names></name><name><surname>Hirumi</surname><given-names>K.</given-names></name></person-group><article-title>Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers</article-title><source>J Parasitol</source><year>1989</year><volume>75</volume><fpage>985</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">2614608</pub-id></citation></ref><ref id="bib22"><label>[22]</label><citation citation-type="other">Leslie A. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography, No. 26; 1992.</citation></ref><ref id="bib23"><label>[23]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W.</given-names></name></person-group><article-title>Evaluation of single-crystal X-ray-diffraction data from a position-sensitive detector</article-title><source>J Appl Cryst</source><year>1988</year><volume>21</volume><fpage>916</fpage><lpage>924</lpage></citation></ref><ref id="bib24"><label>[24]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Bond</surname><given-names>C.S.</given-names></name><name><surname>Bailey</surname><given-names>S.</given-names></name></person-group><article-title>The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3&#x000c5; resolution</article-title><source>Protein Sci</source><year>1996</year><volume>5</volume><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">8771196</pub-id></citation></ref><ref id="bib25"><label>[25]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vagin</surname><given-names>A.</given-names></name><name><surname>Teplyakov</surname><given-names>A.</given-names></name></person-group><article-title>MOLREP: an automated program for molecular replacement</article-title><source>J Appl Cryst</source><year>1997</year><volume>30</volume><fpage>1022</fpage><lpage>1025</lpage></citation></ref><ref id="bib26"><label>[26]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P.</given-names></name><name><surname>Cowtan</surname><given-names>K.</given-names></name></person-group><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallogr D</source><year>2004</year><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="pmid">15572765</pub-id></citation></ref><ref id="bib27"><label>[27]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murshudov</surname><given-names>G.N.</given-names></name><name><surname>Vagin</surname><given-names>A.A.</given-names></name><name><surname>Dodson</surname><given-names>E.J.</given-names></name></person-group><article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title><source>Acta Crystallogr D</source><year>1997</year><volume>53</volume><fpage>240</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">15299926</pub-id></citation></ref><ref id="bib28"><label>[28]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>CCP4</surname></name></person-group><article-title>The CCP4 suite: programs for protein crystallography</article-title><source>Acta Crystallogr D</source><year>1994</year><volume>50</volume><fpage>760</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">15299374</pub-id></citation></ref><ref id="bib29"><label>[29]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>M.L.</given-names></name><name><surname>Fairlamb</surname><given-names>A.H.</given-names></name></person-group><article-title>Trypanothione reductase from Leishmania donovani&#x02014;purification, characterisation and inhibition by trivalent antimonials</article-title><source>Eur J Biochem</source><year>1995</year><volume>230</volume><fpage>460</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">7607216</pub-id></citation></ref><ref id="bib30"><label>[30]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>F.X.</given-names></name><name><surname>Shames</surname><given-names>S.L.</given-names></name><name><surname>Walsh</surname><given-names>C.T.</given-names></name></person-group><article-title>Expression of Trypanosoma congolense trypanothione reductase in Escherichia coli: overproduction, purification, and characterization</article-title><source>Biochemistry</source><year>1989</year><volume>28</volume><fpage>4986</fpage><lpage>4992</lpage><pub-id pub-id-type="pmid">2669965</pub-id></citation></ref><ref id="bib31"><label>[31]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krauth-Siegel</surname><given-names>R.L.</given-names></name><name><surname>Enders</surname><given-names>B.</given-names></name><name><surname>Henderson</surname><given-names>G.B.</given-names></name></person-group><article-title>Trypanothione reductase from Trypanosoma cruzi: purification and characterization of the crystalline enzyme</article-title><source>Eur J Biochem</source><year>1987</year><volume>164</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">3549299</pub-id></citation></ref><ref id="bib32"><label>[32]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shames</surname><given-names>S.L.</given-names></name><name><surname>Fairlamb</surname><given-names>A.H.</given-names></name><name><surname>Cerami</surname><given-names>A.</given-names></name></person-group><article-title>Purification and characterization of trypanothione reductase from Crithidia fasciculata, a newly discovered member of the family of disulphide-containing flavoprotein reductases</article-title><source>Biochemistry</source><year>1986</year><volume>25</volume><fpage>3519</fpage><lpage>3526</lpage><pub-id pub-id-type="pmid">3718941</pub-id></citation></ref><ref id="bib33"><label>[33]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>J.L.</given-names></name><name><surname>Nett</surname><given-names>I.R.E.</given-names></name><name><surname>Jones</surname><given-names>D.C.</given-names></name></person-group><article-title>Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis</article-title><source>ChemMedChem</source><year>2009</year><volume>4</volume><fpage>1333</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">19557801</pub-id></citation></ref><ref id="bib34"><label>[34]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>T.</given-names></name><name><surname>Sano</surname><given-names>K.</given-names></name><name><surname>Takakura</surname><given-names>K.</given-names></name></person-group><article-title>Ebselen in acute ischemic stroke&#x02014;a placebo-controlled, double-blind clinical trial</article-title><source>Stroke</source><year>1998</year><volume>29</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">9445321</pub-id></citation></ref><ref id="bib35"><label>[35]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivarola</surname><given-names>H.W.</given-names></name><name><surname>Paglini-Oliva</surname><given-names>P.A.</given-names></name></person-group><article-title>Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas&#x02019; disease evolution</article-title><source>Curr Drug Targets Cardiovasc Haematol Disord</source><year>2002</year><volume>2</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12769656</pub-id></citation></ref><ref id="bib36"><label>[36]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>T.J.</given-names></name><name><surname>McKie</surname><given-names>J.H.</given-names></name><name><surname>Garforth</surname><given-names>J.</given-names></name></person-group><article-title>Rationally designed selective inhibitors of trypanothione reductase: phenothiazines and related tricyclics as lead structures</article-title><source>Biochem J</source><year>1992</year><volume>286</volume><fpage>9</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">1355650</pub-id></citation></ref><ref id="bib37"><label>[37]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>H.</given-names></name><name><surname>Ruben</surname><given-names>L.</given-names></name><name><surname>Gould</surname><given-names>S.</given-names></name></person-group><article-title>Phenothiazines in murine African trypanosomiasis</article-title><source>Trans R Soc Trop Med Hyg</source><year>1987</year><volume>81</volume><fpage>932</fpage><pub-id pub-id-type="pmid">3503414</pub-id></citation></ref><ref id="bib38"><label>[38]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>G.A.</given-names></name><name><surname>Charman</surname><given-names>W.N.</given-names></name><name><surname>Fairlamb</surname><given-names>A.H.</given-names></name></person-group><article-title>Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with anti-parasitic activity</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>2824</fpage><lpage>2833</lpage><pub-id pub-id-type="pmid">19364854</pub-id></citation></ref><ref id="bib39"><label>[39]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C.A.</given-names></name><name><surname>Lombardo</surname><given-names>F.</given-names></name><name><surname>Dominy</surname><given-names>B.W.</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source>Adv Drug Deliv Rev</source><year>2001</year><volume>46</volume><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">11259830</pub-id></citation></ref><ref id="bib40"><label>[40]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>S.</given-names></name><name><surname>Jones</surname><given-names>D.C.</given-names></name><name><surname>Shanks</surname><given-names>E.J.</given-names></name></person-group><article-title>Synthesis and evaluation of 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductase</article-title><source>ChemMedChem</source><year>2009</year><volume>4</volume><fpage>1341</fpage><lpage>1353</lpage><pub-id pub-id-type="pmid">19557802</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Fig. 1</label><caption><p>Trypanothione reductase assay principle. Panel A, structure of trypanothione disulphide. Panel B, in the DTNB-coupled assay trypanothione is recycled to trypanothione disulphide by the reduction of DTNB. Formation of thionitrobenzoate anion (TNB<sup>-</sup>) is monitored at 412&#x000a0;nm. Panel C, in a modification of the DTNB-coupled assay NADPH is recycled by the enzyme glucose-6-phosphate dehydrogenase.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Fig. 2</label><caption><p>Analysis of trypanothione reductase purification by SDS-PAGE. Lane 1, crude cell lysate (2&#x000a0;&#x003bc;g); lane 2, protein after 35&#x02013;70% ammonium sulphate cut (2&#x000a0;&#x003bc;g); lane 3, eluate from 2&#x02032;5&#x02032;-ADP Sepharose column (1&#x000a0;&#x003bc;g); lane 4, eluate from Q-Sepharose column (1&#x000a0;&#x003bc;g); lane 5, purified <italic>T. cruzi</italic> recombinant trypanothione reductase (0.2&#x000a0;&#x003bc;g).</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Fig. 3</label><caption><p>Absorption spectra of purified <italic>TbTryR</italic>. Solid line, oxidised enzyme; dashed line, 30&#x000a0;min after addition 2&#x000a0;mM NADPH.</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Fig. 4</label><caption><p>Structures of inhibitors tested against <italic>Tb</italic>TryR and <italic>Tc</italic>TryR. The following compounds were tested for potency of inhibition against <italic>Tb</italic>TryR and <italic>Tc</italic>TryR, see <xref rid="tbl3" ref-type="table">Table 3</xref>.</p></caption><graphic xlink:href="gr4"/></fig><fig id="fig5"><label>Fig. 5</label><caption><p><italic>K</italic><sub>i</sub> determination of <italic>Tb</italic>TryR with respect to clomipramine. T(S)<sub>2</sub> was varied as the substrate to confirm the mode of clomipramine inhibition and the <italic>K</italic><sub>i</sub> value. An <italic>F</italic>-test confirmed the mode of inhibition as linear competitive. Clomipramine was added at 0&#x000a0;&#x003bc;M (open circles); 1&#x000a0;&#x003bc;M (closed circles); 2&#x000a0;&#x003bc;M (open squares) and 4&#x000a0;&#x003bc;M (closed squares).</p></caption><graphic xlink:href="gr5"/></fig><fig id="fig6"><label>Fig. 6</label><caption><p>Crystal structure of <italic>Tb</italic>TryR. Panel A, the crystal structure is coloured to differentiate the two subunits forming the homodimer. FAD is shown in red and NADPH in blue. Panel B, a close-up of the <italic>Tb</italic>TryR active site (purple and yellow) superimposed onto the <italic>Tc</italic>TryR active site (black and grey, pdb code <ext-link xlink:href="pdb:1BZN" ext-link-type="uri">1BZN</ext-link> ). Trypanothione is shown bound into the active site of the <italic>Tc</italic>TryR structure.</p></caption><graphic xlink:href="gr6"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Purification of recombinant <italic>T. b. brucei</italic> trypanothione reductase from <italic>E. coli</italic>. Activity was measured in the standard 340&#x000a0;nm assay as described in the methods.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Step</th><th align="left">Volume (ml)</th><th align="left">Total protein (mg)</th><th align="left">Specific activity (U&#x000a0;mg<sup>&#x02212;1</sup>)</th><th align="left">Total activity (U)</th><th align="left">Purification factor <italic>x</italic>-fold</th><th align="left">Yield (%)</th></tr></thead><tbody><tr><td align="left">Cell lysate</td><td align="char">40</td><td align="char">182</td><td align="char">2.4</td><td align="char">442</td><td align="char">1</td><td align="char">100</td></tr><tr><td align="left">35&#x02013;70% (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub></td><td align="char">10.0</td><td align="char">96.3</td><td align="char">3.4</td><td align="char">326</td><td align="char">1.4</td><td align="char">74</td></tr><tr><td align="left">2&#x02032;5&#x02032;-ADP-Sepharose</td><td align="char">17.8</td><td align="char">4.5</td><td align="char">78.4</td><td align="char">353</td><td align="char">32</td><td align="char">80</td></tr><tr><td align="left">Q-Sepharose</td><td align="char">2.1</td><td align="char">2.8</td><td align="char">91.0</td><td align="char">258</td><td align="char">38</td><td align="char">58</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Trypanothione reductase spectral properties and kinetic parameters. <italic>K</italic><sub>m</sub> values for T(S)<sub>2</sub> were determined for <italic>Tb</italic>TryR and <italic>Tc</italic>TryR in both the 340 and 412&#x000a0;nm assays. Additional data from <italic>L. donovani</italic><xref rid="bib29" ref-type="bibr">[29]</xref> and <italic>T. cruzi</italic><xref rid="bib12 bib31" ref-type="bibr">[12,31]</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Units</th><th align="left"><italic>T. b. brucei</italic></th><th align="left"><italic>T. cruzi</italic></th><th align="left"><italic>L. donovani</italic></th></tr></thead><tbody><tr><td colspan="5" align="left">Spectral properties</td></tr><tr><td align="left">&#x000a0;<italic>&#x003bb;</italic><sub>max</sub> (oxidised enzyme)</td><td align="left">nm</td><td align="left">463</td><td align="left">464</td><td align="left">463</td></tr><tr><td align="left">&#x000a0;<italic>&#x0025b;</italic><sub>0</sub> at <italic>&#x003bb;</italic><sub>max</sub></td><td align="left">mM<sup>&#x02212;1</sup>&#x000a0;cm<sup>&#x02212;1</sup></td><td align="left">11.4&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">11.4</td><td align="left">11.5</td></tr><tr><td align="left">&#x000a0;Charge transfer band (reduced enzyme)</td><td align="left">&#x02013;</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">&#x000a0;<italic>&#x0025b;</italic><sub>0</sub> at <italic>&#x003bb;</italic><sub>530&#x000a0;nm</sub></td><td align="left">mM&#x000a0;cm<sup>&#x02212;1</sup></td><td align="left">4.1</td><td align="left">4.9</td><td align="left">4.2</td></tr><tr><td colspan="5" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="5" align="left">Enzymatic properties</td></tr><tr><td align="left">&#x000a0;Specific activity</td><td align="left">U&#x000a0;mg<sup>&#x02212;1</sup></td><td align="left">91</td><td align="left">143</td><td align="left">113</td></tr><tr><td align="left">&#x000a0;<italic>K</italic><sub>m</sub> NADPH (by DTNB-coupled assay)</td><td align="left">&#x003bc;M</td><td align="left">0.77&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="left">n.d.<xref rid="tbl2fn1" ref-type="table-fn">a</xref></td><td align="left">n.d.<xref rid="tbl2fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left">&#x000a0;<italic>K</italic><sub>m</sub> T(S)<sub>2</sub> (by DTNB-coupled assay)</td><td align="left">&#x003bc;M</td><td align="left">2.35&#x000a0;&#x000b1;&#x000a0;0.07</td><td align="left">10.4&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">n.d.<xref rid="tbl2fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left">&#x000a0;<italic>K</italic><sub>m</sub> T(S)<sub>2</sub> (by NADPH oxidation)</td><td align="left">&#x003bc;M</td><td align="left">6.9&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">29.6&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="left">36</td></tr><tr><td align="left">&#x000a0;<italic>k</italic><sub>cat</sub> (by NADPH oxidation)</td><td align="left">s<sup>&#x02212;1</sup></td><td align="left">46.8&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left">77&#x000a0;&#x000b1;&#x000a0;8.0</td><td align="left">179</td></tr><tr><td align="left">&#x000a0;<italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub></td><td align="left">M<sup>&#x02212;1</sup>&#x000a0;s<sup>&#x02212;1</sup></td><td align="left">8.7&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup></td><td align="left">2.6&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup></td><td align="left">5&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup></td></tr></tbody></table><table-wrap-foot><fn id="tbl2fn1"><label>a</label><p>n.d.: not determined.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Potency of representative compounds against trypanothione reductase from <italic>T. b. brucei</italic> and <italic>T. cruzi</italic> and growth inhibition of <italic>T. b. brucei</italic> cells<italic>.</italic> All IC<sub>50</sub> values against <italic>Tb</italic>TryR and <italic>Tc</italic>TryR were determined in the 412&#x000a0;nm assay on three separate occasions. IC<sub>50</sub> values were determined with T(S)<sub>2</sub> at S&#x000a0;=&#x000a0;<italic>K</italic><sub>m</sub> (2.35&#x000a0;&#x003bc;M for <italic>Tb</italic>TryR and 10.4&#x000a0;&#x003bc;M for <italic>Tc</italic>TryR). For structures see <xref rid="fig4" ref-type="fig">Fig. 4</xref>. Linear regression analysis of IC<sub>50</sub> for <italic>Tb</italic>TryR versus EC<sub>50</sub> for <italic>T. brucei</italic> yielded a regression coefficient of <italic>r</italic><sup>2</sup>&#x000a0;=&#x000a0;0.49.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Compound</th><th colspan="2" align="left">IC<sub>50</sub> (&#x003bc;M)<hr/></th><th align="left">Ratio</th><th align="left">EC<sub>50</sub> (&#x003bc;M)</th></tr><tr><th/><th align="left"><italic>Tb</italic>TryR</th><th align="left"><italic>Tc</italic>TryR</th><th align="left"><italic>Tc/Tb</italic></th><th align="left"><italic>T. b. brucei</italic></th></tr></thead><tbody><tr><td align="left">Ebselen</td><td align="char">0.18&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="char">0.60&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="char">3.3</td><td align="left">2.97<xref rid="tbl3fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left">DM8a</td><td align="char">3.17&#x000a0;&#x000b1;&#x000a0;0.17</td><td align="char">7.99&#x000a0;&#x000b1;&#x000a0;0.51</td><td align="char">2.5</td><td align="left">1.00&#x000a0;&#x000b1;&#x000a0;0.21<xref rid="tbl3fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left">DM6a</td><td align="char">3.20&#x000a0;&#x000b1;&#x000a0;0.16</td><td align="char">3.80&#x000a0;&#x000b1;&#x000a0;0.20</td><td align="char">1.2</td><td align="left">0.68&#x000a0;&#x000b1;&#x000a0;0.10<xref rid="tbl3fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left">DM5a</td><td align="char">6.80&#x000a0;&#x000b1;&#x000a0;0.42</td><td align="char">16.9&#x000a0;&#x000b1;&#x000a0;1.08</td><td align="char">2.5</td><td align="left">0.55&#x000a0;&#x000b1;&#x000a0;0.04<xref rid="tbl3fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left">Thioridazine</td><td align="char">9.58&#x000a0;&#x000b1;&#x000a0;0.38</td><td align="char">10.0&#x000a0;&#x000b1;&#x000a0;0.31</td><td align="char">1.0</td><td align="left">1.39&#x000a0;&#x000b1;&#x000a0;0.03</td></tr><tr><td align="left">Clomipramine</td><td align="char">11.1&#x000a0;&#x000b1;&#x000a0;0.42</td><td align="char">3.41&#x000a0;&#x000b1;&#x000a0;0.06</td><td align="char">0.3</td><td align="left">5.04<xref rid="tbl3fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left">DM7a</td><td align="char">19.2&#x000a0;&#x000b1;&#x000a0;1.75</td><td align="char">27.8&#x000a0;&#x000b1;&#x000a0;2.08</td><td align="char">1.4</td><td align="left">3.01&#x000a0;&#x000b1;&#x000a0;0.3<xref rid="tbl3fn2" ref-type="table-fn">b</xref></td></tr><tr><td align="left">Quinacrine</td><td align="char">22.1&#x000a0;&#x000b1;&#x000a0;2.05</td><td align="char">37.8&#x000a0;&#x000b1;&#x000a0;1.91</td><td align="char">1.7</td><td align="left">n.d.</td></tr><tr><td align="left">Trifluoperazine</td><td align="char">40.5&#x000a0;&#x000b1;&#x000a0;1.50</td><td align="char">20.9&#x000a0;&#x000b1;&#x000a0;0.90</td><td align="char">0.5</td><td align="left">2.11&#x000a0;&#x000b1;&#x000a0;0.50</td></tr><tr><td align="left">Citalopram</td><td align="char">82.3&#x000a0;&#x000b1;&#x000a0;6.35</td><td align="char">154&#x000a0;&#x000b1;&#x000a0;5.42</td><td align="char">1.9</td><td align="left">6.59&#x000a0;&#x000b1;&#x000a0;0.54</td></tr></tbody></table><table-wrap-foot><fn id="tbl3fn1"><label>a</label><p>Data from Richardson et al. <xref rid="bib33" ref-type="bibr">[33]</xref>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn2"><label>b</label><p>Data from Martyn et al. <xref rid="bib19" ref-type="bibr">[19]</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p>Crystallography statistics.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Space group</td><td align="left"><italic>P2</italic><sub><italic>1</italic></sub><italic>2</italic><sub><italic>1</italic></sub><italic>2</italic><sub><italic>1</italic></sub></td></tr><tr><td align="left">Cell dimensions: <italic>a</italic>, <italic>b</italic>, <italic>c</italic> (&#x000c5;)</td><td align="left">63.63, 132.71, 161.28</td></tr><tr><td align="left">Cell angles: <italic>&#x003b1;</italic>&#x000a0;=&#x000a0;<italic>&#x003b2;</italic>&#x000a0;=&#x000a0;<italic>&#x003b3;</italic> (&#x000b0;)</td><td align="left">90</td></tr><tr><td align="left">Molecules per asymmetric unit</td><td align="left">2</td></tr><tr><td align="left">Resolution (&#x000c5;)</td><td align="left">2.3</td></tr><tr><td align="left">Measured reflections</td><td align="left">292,320</td></tr><tr><td align="left">Unique reflections</td><td align="left">58,415</td></tr><tr><td align="left">Completeness (%)</td><td align="left">94.9 (85.7)<xref rid="tbl4fn1" ref-type="table-fn">a</xref></td></tr><tr><td align="left">Redundancy</td><td align="left">5.0 (3.4)</td></tr><tr><td align="left"><italic>R</italic><sub>sym</sub> (%)</td><td align="left">0.049 (0.099)</td></tr><tr><td align="left">&#x02329;<italic>I</italic>/<italic>&#x003c3;</italic> (<italic>I</italic>)&#x0232a;</td><td align="left">22.9 (9.2)</td></tr><tr><td align="left">Wilson <italic>B</italic> (&#x000c5;<sup>2</sup>)</td><td align="left">29</td></tr><tr><td align="left">Overall <italic>B</italic>-factor (&#x000c5;<sup>2</sup>)</td><td align="left">21.0</td></tr><tr><td align="left"><italic>R</italic><sub>free</sub> (5% of reflections)</td><td align="left">0.227</td></tr><tr><td align="left"><italic>R</italic><sub>factor</sub></td><td align="left">0.181</td></tr><tr><td align="left">Cruickshanks DPI</td><td align="left">0.273</td></tr></tbody></table><table-wrap-foot><fn id="tbl4fn1"><label>a</label><p>The numbers in parentheses refer to the highest resolution bin (2.36&#x02013;2.30&#x000a0;&#x000c5;).</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 